Table 2.
Characteristics | Total | Pre-Vaccine Introduction (%) | Post-Vaccine Introduction (%) | p-Value |
---|---|---|---|---|
Number of Samples Tested | 984 | 454 (46.1) | 530 (53.9) | |
Samples Tested (Year) | ||||
2003 | 223 | 223 | - | |
2013 | 231 | 231 | - | |
2016 | 239 | - | 239 | |
2019 | 291 | - | 291 | |
Gender | 0.847 | |||
Male | 570 (57.9) | 261 (57.5) | 309 (58.3) | |
Female | 414 (42.1) | 193 (42.5) | 221 (41.7) | |
Age | ||||
Mean (SD) | 15 (11.2) | 13.4 (9.9) | 16.3 (12) | <0.001 |
Median (IQR) | 11.7 (7.3–19.3) | 11.2 (6.8–16.5) | 12.5 (7.9–21) | <0.001 |
Age group | 0.003 | |||
0–11 Months | 505 (51.3) | 252 (55.5) | 253 (47.7) | |
12–23 Months | 323 (32.8) | 148 (32.6) | 175 (33.0) | |
24–59 Months | 156 (15.9) | 54 (11.9) | 102 (19.3) | |
Disease Severity in RVA Cases = n (139) | ||||
Mild | 12 (8.6) | 7 (10.6) | 5 (6.8) | 0.441 |
Moderate | 50 (36.0) | 26 (39.4) | 24 (32.9) | |
Severe | 77 (55.4) | 33 (50) | 44 (60.3) | |
Discharge Outcome = n (982) # | 0.556 | |||
Alive | 925 (94.2) | 425 (93.6) | 500 (94.7) | |
Dead | 57 (5.8) | 29 (6.4) | 28 (5.3) |
SD means standard deviation; IQR means interquartile range; RVA means rotavirus group A. Values given are the counts and percentages are provided in brackets. # Discharge outcome for two subjects was missing. Disease Severity Was Calculated Using the Vesikari Clinical Severity Scoring System Manual [10].